M&A Deal Summary |
|
|---|---|
| Date | 2013-09-10 |
| Target | Flowsense Medical |
| Sector | Healthcare Services |
| Buyer(s) | Baxter International |
| Deal Type | Add-on Acquisition |
| Deal Value | 10M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1931 |
| Sector | Medical Products |
| Employees | 38,000 |
| Revenue | 10.6B USD (2024) |
Baxter International develops, manufactures and markets drugs and medical products for people with a variety of medical conditions. Baxter's operations are comprised of the BioScience and Medical Products segments. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. Baxter International was founded in 1931 and is based in Deerfield, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 12 of 20 |
| Sector: Healthcare Services M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 10 of 14 |
| Country: Israel M&A | 1 of 1 |
| Year: 2013 M&A | 2 of 2 |
| Size (of disclosed) | 17 of 17 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-09-06 |
Gambro AB
Stockholm, Sweden Gambro is a global medical technology company and a leader in developing, manufacturing and supplying products, therapies and services for In-center Care and Self Care hemodialysis, Peritoneal Dialysis, Renal Intensive Care and Hepatic Care. Gambro was founded in 1964 and has more than 8,000 employees, production facilities in 11 countries, sales subsidiaries in more than 40 and sales in more than 100 countries. |
Buy | $3.9B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-04-02 |
Chatham Therapeutics
United States Chatham Therapeutics, LLC (Chatham) is a privately held clinical development-stage biotechnology company engaged in the development of novel, gene therapy-mediated treatments for hemophilia. The company is currently engaged in gene therapy-based therapeutic programs for both hemophilia A and B. |
Buy | $70M |
